Unprecedented Diabetes Research Collaboration to Lead to Expedited PharmaCyte Biotech Clinical Trials

BALTIMORE, Apr. 28, 2015 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the new, sponsored research article, previous reports, updates and articles, along with disclosures and disclaimers, or to download them in their entirety, please visit www.GoldmanResearch.com. 

In the update, analyst Rob Goldman discusses how current and future diabetes research collaboration should lead to expedited human clinical trials.

"One of the untold stories behind PharmaCyte Biotech's success is that the formation and implementation of its International Diabetes Consortium has already resulted in unique and unprecedented collaboration on diabetes research which should lead to expedited clinical trials. The 16-member group, which boasts top tier scientists and doctors in the field of diabetes research and treatment, has members concurrently leading PharmaCyte Biotech-related diabetes research projects in more than half a dozen universities in Europe and Asia."

"Typically, preclinical research and animal studies are performed and executed one at a time. The Consortium's multiple studies are being simultaneously implemented with slightly different designs and objectives in order to accelerate the R&D process. This streamlining should substantially reduce the time to human clinical trials."

Goldman commented further, "PharmaCyte Biotech has the exclusive worldwide rights to use Melligen cells to treat diabetes which in recent tests have demonstrated that they appear to have the ability to reverse the diabetic condition in diabetic mice. Today, all members of the Consortium are committed to developing a treatment for insulin-dependent diabetes using PharmaCyte Biotech's Cell-in-a-Box® cellulose-based live-cell encapsulation technology combined with human non-pancreatic, insulin-producing cells (Melligen Cells).  To swiftly reach this objective, Consortium members are leveraging their individual strengths and animal studies capabilities, by working concurrently and in tandem.  As a result, the Consortium's diabetes research studies may be some of the comprehensive concurrent efforts undertaken in years. "

"Once all of the mice studies are completed, PharmaCyte Biotech can leverage the Consortium's research facilities and personnel at leading universities and companies to migrate to pig studies, since pigs are biologically and anatomically close to humans and the pig trials will thus lead to human clinical trials. Upon successful completion of these Cell-in-a-Box®/Melligen tests, the Company will move to the clinic in order to demonstrate the reversal of diabetes in humans." 

In the article, Goldman noted, "The value proposition provided PharmaCyte Biotech in the Consortium's efforts is clear and a higher valuation should be afforded the Company each time a key research stage is completed, which should occur in the coming quarters, as outlined above."  

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Since March 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $11,000 for investment research services that includes the publication of a research report, research updates and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]

SOURCE Goldman Small Cap Research

Related Links

http://www.GoldmanResearch.com